Barbara Ryan

Resurgence offers a mixed bag as capital crunch continues for many.

The recent rally in the sector may have legs.

Projecting the viability of the JPM jumpstart over the long haul.

There’s reason to believe that a positive pivot may be in the offing.

Could the sector please get a little ‘rate’ relief?

When you know it is coming—but it takes forever to get there.

Strong economic data in other sectors mean rising ‘real’ rates.

Could the sector be nearing a turning point in performance?

But will Washington’s dealmaking stance upend the momentum?

Such a scenario is one possibility as the bear market languishes on.

The ‘blistering’ pace may further divide the haves from the have-nots.

Over two years into a bear market, it still can’t catch a sustainable bid.

Is stock market outperformance for biotech still in the cards for 2023?

Chronicling the market’s rise and fall—and signs of potential recovery.

What a changing economy and related trends could mean for 2023.

Perspectives from a board member and an aspiring board member on how to increase the number of qualified women on boards.

Will biopharma investment heat up and signal better fortunes for 2023?

Focus is on cash: who’s got it, who doesn’t, and what will it mean?

As fundamentals improve, potential rate plateau could ignite growth.

Biotech stocks and the indexes have staged an impressive recovery.

A look at the driving factors behind renewed optimism.

A summary of key takeaways from EY’s new Beyond Borders report.

Some observations point to hope for an upturn.

Living to fight another day, as potential investment spark looms.

What will current stranglehold mean for industry down the line?

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.